Inhibrx Biosciences (INBX) Institutional Ownership
13F filers reported holding 11.8% of Inhibrx Biosciences (INBX) shares as of Sep 30, 2026, across 50 filers.
- Held by 13F filers
- 11.8%
- Sep 30, 2026
- 13F filers
- 50
- quarter ended Sep 30, 2026
- 13F value
- $174.4M
- 1.7M shares
- Quarter's fund flow
- Mild accumulation
- 13 new · 9 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 2,470 | $84.07 | ↗ |
| Oct 14, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 2,470 | $85.00 | ↗ |
| Oct 14, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 100 | $85.76 | ↗ |
| Oct 14, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 2,449 | $84.07 | ↗ |
| Oct 14, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 2,451 | $85.00 | ↗ |
| Oct 14, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 100 | $85.76 | ↗ |
| Sep 28, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 1,500 | $98.88 | ↗ |
| Sep 28, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 3,000 | $101.70 | ↗ |
| Sep 25, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 3,324 | $98.87 | ↗ |
| Sep 25, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 2,176 | $99.60 | ↗ |
| Sep 23, 2026 | Kayyem Jon Faiz | director | Acquired · Open-market buy | 5,000 | $100.00 | ↗ |
| Sep 16, 2026 | Kayyem Jon Faiz | director | Acquired · Open-market buy | 5,000 | $100.00 | ↗ |
| Sep 15, 2026 | MANHARD KIMBERLY | director | Disposed · Open-market sale | 500 | $105.05 | ↗ |
| Sep 14, 2026 | MANHARD KIMBERLY | director | Disposed · Open-market sale | 500 | $110.26 | ↗ |
| Sep 11, 2026 | MANHARD KIMBERLY | director | Disposed · Open-market sale | 500 | $111.78 | ↗ |
| Sep 9, 2026 | MANHARD KIMBERLY | director | Disposed · Open-market sale | 500 | $115.80 | ↗ |
| Sep 8, 2026 | MANHARD KIMBERLY | director | Disposed · Open-market sale | 500 | $115.14 | ↗ |
| Sep 8, 2026 | Kayyem Jon Faiz | director | Acquired · Open-market buy | 5,000 | $113.52 | ↗ |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 5,895 | $99.29 | ↗ |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer | Acquired · Open-market buy | 6,605 | $100.64 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Inhibrx Biosciences do institutions hold?
13F filers reported holding 11.8% of Inhibrx Biosciences' shares as of Sep 30, 2026, across 50 filers.
How many 13F filers hold Inhibrx Biosciences?
Inhibrx Biosciences was held by 50 13F filers as of Sep 30, 2026.
Not investment advice.

